全文获取类型
收费全文 | 142170篇 |
免费 | 12938篇 |
国内免费 | 8583篇 |
专业分类
耳鼻咽喉 | 1388篇 |
儿科学 | 2029篇 |
妇产科学 | 2690篇 |
基础医学 | 16760篇 |
口腔科学 | 2741篇 |
临床医学 | 18908篇 |
内科学 | 22039篇 |
皮肤病学 | 1298篇 |
神经病学 | 7364篇 |
特种医学 | 4917篇 |
外国民族医学 | 57篇 |
外科学 | 15205篇 |
综合类 | 21307篇 |
现状与发展 | 35篇 |
一般理论 | 35篇 |
预防医学 | 8944篇 |
眼科学 | 4124篇 |
药学 | 14423篇 |
109篇 | |
中国医学 | 7121篇 |
肿瘤学 | 12197篇 |
出版年
2024年 | 430篇 |
2023年 | 2173篇 |
2022年 | 5404篇 |
2021年 | 7059篇 |
2020年 | 5077篇 |
2019年 | 4563篇 |
2018年 | 4934篇 |
2017年 | 4199篇 |
2016年 | 4023篇 |
2015年 | 6196篇 |
2014年 | 7850篇 |
2013年 | 7084篇 |
2012年 | 10419篇 |
2011年 | 11408篇 |
2010年 | 7033篇 |
2009年 | 5560篇 |
2008年 | 7371篇 |
2007年 | 7564篇 |
2006年 | 7474篇 |
2005年 | 7444篇 |
2004年 | 5101篇 |
2003年 | 4495篇 |
2002年 | 3913篇 |
2001年 | 3239篇 |
2000年 | 3397篇 |
1999年 | 3494篇 |
1998年 | 2068篇 |
1997年 | 1937篇 |
1996年 | 1659篇 |
1995年 | 1472篇 |
1994年 | 1295篇 |
1993年 | 817篇 |
1992年 | 1223篇 |
1991年 | 986篇 |
1990年 | 829篇 |
1989年 | 783篇 |
1988年 | 722篇 |
1987年 | 662篇 |
1986年 | 479篇 |
1985年 | 398篇 |
1984年 | 252篇 |
1983年 | 184篇 |
1982年 | 111篇 |
1981年 | 123篇 |
1980年 | 101篇 |
1979年 | 139篇 |
1978年 | 65篇 |
1977年 | 61篇 |
1975年 | 53篇 |
1974年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Yan Gao Shi-Feng Chu Zhao Zhang Qi-Di Ai Cong-Yuan Xia Hui-Yong Huang 《Journal of Asian natural products research》2019,21(8):782-797
Inappropriate use of acetaminophen (APAP) can lead to morbidity and mortality secondary to hepatic necrosis. Ginsenoside Rg1 is a major active ingredient in processed Panax ginseng, which is proved to elicit biological effects. We hypothesized the beneficial effect of Rg1 on APAP-mediated hepatotoxicity was through Nrf2/ARE pathway. The study was conducted in cells and mice, comparing the actions of Rg1. Rg1 significantly improved cell survival rates and promoted the expression of antioxidant proteins. Meanwhile, Rg1 reduced the excessive ROS and the occurrence of cell apoptosis, which were related to Nrf2/ARE pathway. Expression of Nrf2 has a certain cell specificity.
12.
13.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
14.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献15.
16.
17.
Y.R. Song B. Wu Y.T. Yang J. Chen L.J. Zhang Z.W. Zhang H.Y. Shi C.L. Huang J.X. Pan P. Xie 《Brazilian journal of medical and biological research》2015,48(11):973-982
Bipolar disorder (BD) is a common psychiatric mood disorder affecting more than 1-2%
of the general population of different European countries. Unfortunately, there is no
objective laboratory-based test to aid BD diagnosis or monitor its progression, and
little is known about the molecular basis of BD. Here, we performed a comparative
proteomic study to identify differentially expressed plasma proteins in various BD
mood states (depressed BD, manic BD, and euthymic BD) relative to healthy controls. A
total of 10 euthymic BD, 20 depressed BD, 15 manic BD, and 20 demographically matched
healthy control subjects were recruited. Seven high-abundance proteins were
immunodepleted in plasma samples from the 4 experimental groups, which were then
subjected to proteome-wide expression profiling by two-dimensional electrophoresis
and matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight tandem
mass spectrometry. Proteomic results were validated by immunoblotting and
bioinformatically analyzed using MetaCore. From a total of 32 proteins identified
with 1.5-fold changes in expression compared with healthy controls, 16 proteins were
perturbed in BD independent of mood state, while 16 proteins were specifically
associated with particular BD mood states. Two mood-independent differential
proteins, apolipoprotein (Apo) A1 and Apo L1, suggest that BD pathophysiology may be
associated with early perturbations in lipid metabolism. Moreover, down-regulation of
one mood-dependent protein, carbonic anhydrase 1 (CA-1), suggests it may be involved
in the pathophysiology of depressive episodes in BD. Thus, BD pathophysiology may be
associated with early perturbations in lipid metabolism that are independent of mood
state, while CA-1 may be involved in the pathophysiology of depressive episodes. 相似文献
18.
患者男,64岁,因头颅增大、面部变长,颧骨隆起、下颌增大、双手掌肥厚、双手指粗短30余年,乳房肿物1年余就诊。患者30余年前无明显诱因出现渐进性手足增大,双手掌肥厚,嘴唇变厚,下颌增大,眉弓及颧骨突出,皮肤增厚,无乳腺增大、泌乳,未诊治…… 相似文献
19.
20.